By Adam Clark

AstraZeneca PLC (AZN.LN) said Friday that the European Medicines Agency has recommended the marketing authorization of its benralizumab drug for asthma treatment.

The pharmaceutical company said the recommendation is based on phase 3 clinical trial data and is an important step towards providing a next-generation treatment for severe, uncontrolled asthma patients.

The positive opinion will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union. The drug is also under regulatory review in the U.S., Japan and several other countries.

Shares are down 54 pence, or 1.1%, at 4908 pence at 1203 GMT.

Write to Adam Clark at adam.clark@dowjones.com; @AdamDowJones

(END) Dow Jones Newswires

November 10, 2017 07:22 ET (12:22 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Astrazeneca